title: [Sodium benzoate in portal-systemic-encephalopathy-induced blood ammonia normalization and clinical improvement. Interim report of a double-blind multicenter trial].
abstract: To investigate the therapeutic efficacy of sodium benzoate (SB) in a cirrotic population with chronic portal systemic encepalopathy (PSE), we performed a double blind, randomised, multicentric, clinical trial, comparing SB versus a standard therapy of lactitol (LA). To perform the study blind, syrups containing the two drugs were prepared. To date 27 patients have been studied. Of these, 12 received SB (5.6 g/day) and 15 received LA (29 g/day). Standard PSE parameters were assessed and hippurate urinary excretion was measured before and after the trial. For the SB group, basal and final PSE index were 0.39 +/- 0.16 and 0.17 +/- 0.1 respectively (p < 0.001). The Group on LA had a PSE index of 0.40 + 0.1 and 0.23 +/- 0.18 (basal and final respectively) (p < 0.001). The final hippurate excretion for SB group was 2498.9 mg/24 h. The hippurate excretion for the LA group suffer no changes (traces). No serious side effects were observed with either therapy. We suggested that SB is a safe, efficacious and comfortable alternate treatment for PSE.
authors.affiliation: Departamento de Gastroenterología Instituto Nacional de la Nutrición "Salvador Zubirán", Vasco de Quiroga No. 15, Tlalpan, México 14000, DF.
authors.forename: M
authors.initials: M
authors.lastname: Uribe
authors.forename: F
authors.initials: F
authors.lastname: Bosques
authors.forename: E
authors.initials: E
authors.lastname: Marín
authors.forename: E
authors.initials: E
authors.lastname: Cervera
authors.forename: S
authors.initials: S
authors.lastname: Gil
authors.forename: J
authors.initials: J
authors.lastname: Luis Poo
authors.forename: D
authors.initials: D
authors.lastname: Garcia Compeán
authors.forename: R
authors.initials: R
authors.lastname: Santoyo
authors.forename: E
authors.initials: E
authors.lastname: Huerta
authors.forename: G
authors.initials: G
authors.lastname: García-Ramos
authors.forename: M
authors.initials: M
authors.lastname: Cadena
authors.forename: A
authors.initials: A
authors.lastname: Merikansky
authors.forename: J
authors.initials: J
authors.lastname: Robledo
authors.forename: M
authors.initials: M
authors.lastname: Cortés
authors.forename: A
authors.initials: A
authors.lastname: Guevara
authors.forename: N
authors.initials: N
authors.lastname: López
authors.forename: A
authors.initials: A
authors.lastname: Aguilar
authors.forename: E
authors.initials: E
authors.lastname: Alejandra Ochoa
mesh_terms: D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006626:Hippurates / Q000652:urine; D006801:Humans; D022124:Hyperammonemia / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D020160:Sodium Benzoate / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D006626:Hippurates; D020160:Sodium Benzoate